Axiom Biosciences (fka Cytonus Therapeutics)
Develops biologic medicines intended to repair damaged tissues and treat difficult diseases.
Raising now
OpenRaising on Wefunder ↗
- As of Nov 1, 2026
- $16,766 raised from 8 investors
- Target, as of Nov 1, 2026
- $1,000,000
- Maximum, as of Nov 1, 2026
- $1,000,000
- Closes
- Apr 30, 2027
As Wefunder reports them, as of Nov 1, 2026
- Security
- equity
- Share class
- preferred
- Share price
- $12.04
- Pre money valuation
- $96,030,426
- Exemption
- Reg CF
- Minimum
- $250
From the SEC Form C
- Security (as filed)
- Preferred Stock
- Price
- $12.04
- Filed
- Oct 27, 2026
- Incorporated in
- DE
- Employees
- 3
- Revenue, last fiscal year
- $1,275,587
- Net income, last fiscal year
- -$2,244,653
EarlySignals' view, not the portal's
Our potential score, six-dimension radar and research are for members.
Figures are the portal's own, as of the date shown. Not investment advice; EarlySignals takes no payment from issuers or portals.